Barbell Medicine Podcast cover image

Episode #222: The Science of Losing Fat vs. Muscle

Barbell Medicine Podcast

00:00

Terzepatide and Weight Loss

The Cermont One trial was done for 72 weeks. There seems to be this dose-dependent relationship between terzepatide and weight loss. Liraglutide is a GLP1 agonist, so a different type of medication but the same family. And they added exercise to the deal to see like, hey, can we prevent lean mass losses?

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app